DYNAMICS OF HEMOPOIETIC PROLIFERATION IN MAN AND MICE STUDIED BY H-3-THYMIDINE INCORPORATION INTO DNA
DYNAMICS OF HEMOPOIETIC PROLIFERATION IN MAN AND MICE STUDIED BY H-3-THYMIDINE INCORPORATION INTO DNA
复制标题
DOI：
10.1111/j.1749-6632.1959.tb36943.x
复制
发表时间：
1959-01-01
期刊：
影响因子：
--
通讯作者：
QUASTLER, H
中科院分区：
文献类型：
--
作者：
CRONKITE, EP;FLIEDNER, TM;QUASTLER, H
氚化胸苷已用于造血功能正常和异常的动物和人类，以研究骨髓细胞增殖的动力学。胸苷仅在细胞分裂准备的 DNA 合成过程中被细胞核吸收。通过剥离胶片放射自显影和经典细胞学方法确定和量化其细胞内位置。在具有正常造血功能的人的骨髓中静脉注射H3-胸苷后，在几分钟内就观察到原始增殖细胞的强烈标记。红细胞前体的最大标记发生在 12 至 24 小时；骨髓前体细胞，在第 3 天和第 4 天之间。第 5 天观察到巨核细胞的最大标记。外周血中大单核细胞的标记发生较早；粒细胞标记高峰出现在第5天和第6天。 H3-胸苷与正常人骨髓一起孵育，导致所有细胞系列中出现重度标记；正常静脉血仅显示一小部分大单核细胞的标记。体外培养的患者骨髓和静脉血的 H3-胸苷摄取模式因不同的造血系统疾病而异。对健康和疾病状态下造血细胞增殖动力学的定量结果进行了初步分析，并指出了解决所涉及的复杂问题的要求。淋巴结和骨髓中脆弱的原始间充质细胞群的强烈标记以及它们在淋巴液和血液中少量出现，证明能够分裂的未成熟细胞不断在全身迁移。据信这是一个新的观察结果，其意义尚不清楚。然而，有趣的是，将这种现象视为另一种通用的生物保护措施，使全能细胞可以在任何时间或地点用于防御、修复或再生受损的骨髓，如放射或其他全部或部分骨髓再生障碍。
Tritiated thymidine has been used in animals and in human beings with normal and abnormal hematopoiesis to study the kinetics of bone-marrow cell proliferation. Thymidine is taken up by the nucleus only during DNA synthesis preparatory to cell division. Its intracellular location was determined and quantified by means of stripping film autoradiography and classic cytology. In the bone marrow of human beings with normal hematopoiesis given H3-thymidine intravenously, intense labeling of primitive proliferating cells was observed within minutes. Maximal labeling of erythrocyte precursors occurred at 12 to 24 hours; myeloid precursors, between the 3d and 4th days. Maximal labeling of megakaryocytes was observed on the 5th day. Labeling in the peripheral blood of large mononuclear cells occurred early; the peak labeling of granulocytes occurred on the 5th and 6th days. H3-thymidine incubated with normal human bone marrow resulted in heavy labeling in all cell series; normal venous blood showed labeling of only a small percentage of the large mononuclear cells. The pattern of H3-thymidine uptake with in vitro incubation of bone marrow and venous blood from patients varied with different hematopoietic disorders. A preliminary analysis of the quantitative results in terms of the kinetics of hematopoietic cell proliferation in health and in disease is made, and the requirements for resolution of the complex problems involved are indicated. The intense labeling of the fragile group of primitive mesenchymal cells in the lymph nodes and bone marrow and their appearance in lymph and blood in small numbers prove that immature cells capable of division are continually migrating throughout the body. It is believed that this is a new observation, the significance of which is not yet clear. However, it is entertaining to consider this phenomenon as another general biological protective measure to make totipotential cells available at any time or place for defense, repair, or repopulation of damaged bone marrow, as in radiation or other total or partial aplasias of the marrow.